POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Inclusion Criteria: * Thirteen years of age or older, 34 kg (75 lb) or more, either sex, and any race; * Coccidioides immitis (C. immitis) or Coccidioides posadasii (C. posadasii) identified by culture or microscopic examination from skeletal disease, chronic active pulmonary disease, or soft tissue disease; * Coccidioidomycosis score of \>=6; * Clinical laboratory safety tests within normal limits or clinically acceptable to the sponsor; * Free of any clinically significant disease that would interfere with study evaluations; * Willing to give written informed consent and able to adhere to study medication dose, mandatory procedures (including human immunodeficiency virus (HIV) testing), and visit schedules; * Able to swallow food or a nutritional supplement; * Use of a medically accepted method of contraception; * Negative serum pregnancy test at Screening and negative urine pregnancy test at Randomization; * Women of childbearing potential not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study. Exclusion Criteria: * Key Exclusion Criteria Excluded Medications at Enrollment * Medications that are known to interact with POS or FLU and that may lead to serious or life threatening side effects within 7 days prior to initiating study drug; * Medications known to lower the serum concentration/efficacy of azole antifungals within 7 days prior to study drug start; * Prior investigational drug use or biologic product administration within 30 days before study drug start; * Prior antifungal treatment for the current episode of infection with a total cumulative dose of \>=8 g of any azole, \>=4 mg/kg of amphotericin B deoxycholate, or \>=20 mg/kg of lipid amphotericin B; * Antiretrovirals that are substrates of CYP3A4 administered to HIV-positive subjects, as it is not currently known how POS or FLU may affect such drugs or the potential to cause adverse reactions. * Excluded Concomitant Conditions * Immediately life-threatening coccidioidomycosis; * Confirmed or suspected meningeal coccidioidomycosis; * Pulmonary coccidioidomycosis in HIV-negative subjects for less than 3 months; * Any condition requiring use of prohibited drugs; * Cluster of Differentiation 4 (CD4) count of \<200 cells/mm3 or any auto-immune deficiency syndrome (AIDS)-defining illness in HIV-positive subjects in the prior 30 days. * Excluded Baseline Laboratory Studies * Moderate or severe liver dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 5 times upper limit of normal (ULN)) or a total bilirubin level or direct bilirubin \> 3 times ULN plus ALT or AST \>2 times ULN (Hy's Rule); * Moderate or severe renal dysfunction (creatinine clearance (CrCl) \<20 mL/min) or dialysis required or expected to be required within the study period; * Electrocardiogram (ECG) with a prolonged QTc interval by manual reading: QTc \>450 msec for males and QTc \>470 msec for females. * General Exclusion Criteria * Prior enrollment in this study or other POS studies; * Failed treatment with FLU or POS at any time in the past; * History of hypersensitivity or idiosyncratic reactions to azole drug therapy; * Women who are pregnant, intend to become pregnant, or are breast-feeding; * Situation or condition that may interfere with optimal participation in the study; Part of the staff personnel directly involved with this study; * Family member of the investigational study staff.